logo
How Climate Change Is Raising Your Grocery Bill

How Climate Change Is Raising Your Grocery Bill

Bloomberg20-07-2025
A 300% spike in Australian lettuce prices. A 50% rise for European olive oil and 80% for US vegetables. Researchers from the Barcelona Supercomputing Center and the European Central Bank have traced back those price jumps to extreme weather they say is linked to climate change.
The group analyzed 16 weather events around the world between 2022 and 2024. Many were so unusual that a given region had experienced nothing like it prior to 2020, according to the analysis, which was published in the peer-reviewed journal Environmental Research Letters on Monday in Europe.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure
EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure

Yahoo

time8 minutes ago

  • Yahoo

EnduroSat and WISeSat.Space Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure

FOR IMMEDIATE RELEASE EnduroSat and Partner to Deliver Quantum-Resilient Secure IoT Nanosatellite Infrastructure Sofia, Bulgaria & Geneva, Switzerland – July 28, 2025 – WISeKey International Holding AG (SIX: WIHN, NASDAQ: WKEY), a leading global cybersecurity, blockchain, and IoT company, via its subsidiary AG, a company that focuses on space technology for secure satellite communication, specifically for IoT applications, and EnduroSat, a leading provider of software-flexible satellites, as part of their strategy to diversify partners in the industry, are pleased to announce the signing of a Memorandum of Understanding (MoU) to establish a framework aimed at achieving a strategic partnership to extend the development and deployment of ultra-secure, quantum-resilient nanosatellite systems for Internet of Things (IoT) applications. The cooperation targets the integration of SEALSQ secure elements, such as the VaultIC292, VaultIC408, and QS7001, into satellite payloads and ground-level endpoints. These components enable strong hardware-based security and digital identity protection, ensuring encrypted communications and trusted authentication across the IoT satellite network. The project aims to implement post-quantum cryptographic (PQC) algorithms, aligned with NIST recommendations such as CRYSTALS-Kyber and CRYSTALS-Dilithium, to safeguard against future quantum computing threats. WISeSat will provide the PQC algorithmic stack and support, while EnduroSat will incorporate these into its satellite and communication platform. EnduroSat brings its expertise in modular satellite design, in-orbit validation, and scalable deployment systems. It will lead the physical integration of SEALSQ secure components into next-generation satellite buses and contribute to the overall mission architecture. WISeSat will support cryptographic integration and field engineering resources, ensuring that each system meets high-security and resilience benchmarks. The partnership further outlines the future integration of post-quantum cryptographic solutions and secure elements into both EnduroSat and WISeSat satellite infrastructures. EnduroSat will also support the design and deployment of WISeSat's future missions, ensuring compliance with defined security and performance requirements. This collaboration builds on WISeSat's successful deployment of its new-generation PQC-ready nanosatellite in December 2025 and EnduroSat's proven record of delivering more than 60+ satellites to orbit for institutional, scientific, and commercial customers. The resulting architecture will offer scalable, tamper-proof IoT connectivity services from Low Earth Orbit (LEO), critical for use-cases in logistics, critical infrastructure, defense, and environmental monitoring. 'This partnership with EnduroSat marks a significant step forward in our mission to deliver quantum-resilient, end-to-end secure satellite infrastructure,' said Carlos Moreira, Founder and CEO of WISeKey. 'By integrating SEALSQ's advanced secure elements into the expanding WISeSat constellation, we are building a tamper-proof communications backbone in space. Together with EnduroSat's modular satellite technology, we are enabling scalable and ultra-secure IoT connectivity services from Low Earth Orbit—critical for securing data and infrastructure in the quantum era.' 'We are excited to initiate this partnership,' said Raycho Raychev, founder & CEO of EnduroSat. 'We hope to accelerate the introduction and establishment of much stronger encryption capabilities into the satellite industry.' About AG is pioneering a transformative approach to IoT connectivity and climate change monitoring through its innovative satellite constellation. By providing cost-effective, secure, and global IoT connectivity, WISeSat is enabling a wide range of applications that support environmental monitoring, disaster management, and sustainable practices. The integration of satellite data with advanced climate models holds great promise for enhancing our understanding of climate change and developing effective strategies to combat its impacts. As the world continues to grapple with the challenges of climate change, initiatives like WISeSat's IoT satellite constellation are essential for creating a more resilient and sustainable future. About WISeKeyWISeKey International Holding Ltd ('WISeKey', SIX: WIHN; Nasdaq: WKEY) is a global leader in cybersecurity, digital identity, and IoT solutions platform. It operates as a Swiss-based holding company through several operational subsidiaries, each dedicated to specific aspects of its technology portfolio. The subsidiaries include (i) SEALSQ Corp (Nasdaq: LAES), which focuses on semiconductors, PKI, and post-quantum technology products, (ii) WISeKey SA which specializes in RoT and PKI solutions for secure authentication and identification in IoT, Blockchain, and AI, (iii) WISeSat AG which focuses on space technology for secure satellite communication, specifically for IoT applications, (iv) Corp which focuses on trusted blockchain NFTs and operates the marketplace for secure NFT transactions, and (v) SEALCOIN AG which focuses on decentralized physical internet with DePIN technology and house the development of the SEALCOIN platform. Each subsidiary contributes to WISeKey's mission of securing the internet while focusing on their respective areas of research and expertise. Their technologies seamlessly integrate into the comprehensive WISeKey platform. WISeKey secures digital identity ecosystems for individuals and objects using Blockchain, AI, and IoT technologies. With over 1.6 billion microchips deployed across various IoT sectors, WISeKey plays a vital role in securing the Internet of Everything. The company's semiconductors generate valuable Big Data that, when analyzed with AI, enable predictive equipment failure prevention. Trusted by the OISTE/WISeKey cryptographic Root of Trust, WISeKey provides secure authentication and identification for IoT, Blockchain, and AI applications. The WISeKey Root of Trust ensures the integrity of online transactions between objects and people. For more information on WISeKey's strategic direction and its subsidiary companies, please visit About EnduroSatEnduroSat is a space infrastructure builder that engineers, builds, and operates exceptional satellites. The company streamlines space missions in LEO and beyond, handling every step from mission design to launch and operations. EnduroSat serves more than 360 customers globally and employs more than 230 space professionals across 6 locations worldwide. For more information, visit DisclaimerThis communication expressly or implicitly contains certain forward-looking statements concerning WISeKey International Holding Ltd and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of WISeKey International Holding Ltd to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. WISeKey International Holding Ltd is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, and it does not constitute an offering prospectus within the meaning of the Swiss Financial Services Act ('FinSA'), the FinSa's predecessor legislation or advertising within the meaning of the FinSA. Investors must rely on their own evaluation of WISeKey and its securities, including the merits and risks involved. Nothing contained herein is, or shall be relied on as, a promise or representation as to the future performance of WISeKey. Press and Investor Contacts WISeKey International Holding LtdCompany Contact: Carlos MoreiraChairman & CEOTel: +41 22 594 3000info@ WISeKey Investor Relations (US) The Equity Group CatiTel: +1 212 836-9611 lcati@ ENDUROSAT EADCompany Contact: Raycho RaychevFounder & CEOinfo@

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively
Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

Yahoo

time8 minutes ago

  • Yahoo

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively

First patient dosed in global pivotal clinical trial program for late infantile/juvenile onset NPC and GM1/GM2 gangliosidoses. Both studies are part of Azafaros' mission to develop treatments for the unmet need of patients with rare lysosomal storage disorders The news follows the company's recent successful €132M Series B financing, aimed at supporting the rapid development of nizubaglustat and the expansion of Azafaros' pipeline to other indications LEIDEN, Netherlands, July 28, 2025--(BUSINESS WIRE)--Azafaros, a company focused on developing treatments for the unmet needs of patients with rare lysosomal storage disorders, today announced that the first patient has been dosed in the company's pivotal, multicenter Phase 3 clinical program to evaluate the safety and efficacy of the company's lead asset, nizubaglustat, in patients with Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses. The initiation of the two Phase 3 studies (NCT07054515) represents a major milestone in Azafaros' commitment to addressing the urgent unmet medical needs of children affected by these devastating neurodegenerative disorders. The Phase 3 program consists of two studies targeting the late-infantile and juvenile-onset forms of NPC, and GM1/GM2 gangliosidoses. The studies aim to assess the potential of nizubaglustat to alter disease progression and improve functional outcomes in these patient populations. Today's news follows the recent, successful completion of an oversubscribed series B financing, raising €132M to support the acceleration of nizubaglustat and the expansion of the company's pipeline to other indications. "The dosing of the first patient in our Phase 3 program with nizubaglustat is a significant achievement for Azafaros and a huge step forward in our efforts to bring new, disease modifying treatments to patients with these seriously debilitating diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, families, clinicians, and advocacy groups who are partnering with us to advance this promising therapy." About the NAVIGATE trial The two 18-month randomized 2 to 1, double-blind, placebo-controlled trials will recruit patients at approximately 35 sites across 15 countries worldwide, including in the US, Europe and Latin America. The studies are expected to enroll around 70 patients. The primary endpoint for both trials is the change from baseline to Month 18 in the Scale for the Assessment and Rating of Ataxia (SARA), with both total and functional SARA scores evaluated. For more information on the Phase 3 program, please visit To enquire about trial participation, email: medinfo@ (if a professional) or patientadvocacy@ (if a patient or caregiver). To protect privacy, avoid including identifying information in the initial message. About nizubaglustat Nizubaglustat is a small molecule, orally available and brain penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and Niemann-Pick disease type C (NPC). Nizubaglustat has received Rare Pediatric Disease Designations (RPDD) for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations (ODD) for GM1 and GM2 gangliosidosis (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation (OMPD) for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA). About GM1 and GM2 gangliosidoses GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available. About Niemann-Pick disease Type C (NPC) Niemann-Pick disease Type C is a progressive, life-limiting, neurological, lysosomal storage disorder, caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of disease can happen throughout the lifespan of an affected individual, from prenatal life through adulthood. About Azafaros Azafaros is a clinical-stage company founded in 2018 with a deep understanding of rare genetic disease mechanisms using compound discoveries made by scientists at Leiden University and Amsterdam UMC and is led by a team of highly experienced industry experts. Azafaros aims to build a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families. By applying its knowledge, network and courage, the Azafaros team challenges traditional development pathways to rapidly bring new drugs to the rare disease patients who need them. Azafaros is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital. View source version on Contacts For further information: Azafaros info@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Every Step Counts, But Do You Really Need 10,000?
Every Step Counts, But Do You Really Need 10,000?

Medscape

time9 minutes ago

  • Medscape

Every Step Counts, But Do You Really Need 10,000?

Good news for the sole: Contrary to popular wisdom, people can get the same health benefits from walking 7000 steps a day as they do from walking 10,000 paces, according to a comprehensive review and meta-analysis published in The Lancet Public Health . 'For all outcomes, health benefits continued to accrue until around 7000 steps,' said Katherine Owen, PhD, biostatistician at the University of Sydney, Sydney, Australia, who led the review. 'After 7000 steps, benefits either plateaued or there were very small additional benefits.' Owen and her colleagues reviewed 57 studies and conducted a meta-analysis on 31 of them, examining the relationship between health and physical activity based on daily steps. The researchers looked at nine different health outcomes: all-cause mortality, the incidence of and deaths from cardiovascular disease, dementia, cancer incidence and mortality, the incidence of type 2 diabetes, depressive symptoms, and falls. Every outcome showed improvement as the amount of daily activity increases, but for most people the benefits tapered off at around 5000-7000 steps per day. Compared with taking just 2000 steps per day, walking approximately 7000 steps per day reduced all-cause mortality by 47% and decreased the incidence of cardiovascular disease by 25%, of cancer by 6%, of type 2 diabetes by 14%, of dementia by 38%, of depression by 22%, and of falls by 28%. The study also highlighted that even modest step counts of around 4000 per day were beneficial compared with lower activity of just 2000 steps. 'Every step counts,' Owen said. 'All physical activity is beneficial, but increasing daily steps to around 7000 steps is optimal to improve all health outcomes.' The conventional wisdom that 10,000 steps per day was the optimal amount has no real basis in fact, said I-Min Lee, MD, epidemiologist at Harvard Medical School, Boston, who was the first to show that the health benefits of daily exercise leveled off after 7500 steps. 'There are quite a bit of data now showing that fewer than 10,000 steps per day brings health benefits,' she said. Lee said that most studies to date have focused on all-cause mortality and cardiovascular health. The new study expands the evidence to other health outcomes, although the data for some conditions, such as diabetes, are relatively sparse. Current guidelines for physical activity, such as those from the US Department of Health and Human Services, recommend 150 minutes per week of moderate-to-vigorous physical activity. However, due to lack of evidence at the time of publication, these guidelines do not include daily step targets. As step tracking technologies have become more common, and data on step-based activity have improved, Lee wants future guidelines to incorporate step targets. 'I don't believe they should replace time targets, since not everybody wants to track their steps,' she said. 'But they should be included.' Owen and Lee declared having no competing interests.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store